High performance liquid chromatography method for measuring content of acipimox capsule
Through high-performance liquid chromatography, the problem of poor sensitivity and accuracy in the measurement of aximus capsule content in the prior art was solved, and efficient and accurate measurement of capsule content was achieved, which simplified the operation process and reduced errors.
Patent Information
- Application Number
- CN202411311693.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, when determining the content of aximus capsules, two steps of dilution are required during the preparation of the test sample solution, and the sensitivity, accuracy and specificity are poor.
Using high performance liquid chromatography, the chromatogram was recorded and the content of aximus capsules was calculated by chromatograph. The reference and test sample solution were prepared. Each ml contained about 0.2 mg of the solution, and the octadecylsilane bonded. Silicone chromatography column, methanol-0.01 mol/L tetrabutyl ammonium hydroxide mobile phase, detection wavelength 264 nm, running time 15 min, flow rate 1.0 ml/min, column temperature 30 ℃, injection volume 10 μl.
The sensitivity and accuracy of determining the content of aximus capsules is improved, the solvent configuration process of the test product is simplified, the operation error is reduced, the detection efficiency is improved, and the secondary dilution step is not allowed.
Smart Images

Figure CN118914409A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of pharmaceutical chemical industry, in particular to a high performance liquid chromatography method for determining the content of acipimox capsules. Background Art
[0002] Acipimox is called Acipimox in English. Acipimox capsule is a lipid-lowering drug used to treat dyslipidemia such as hypertriglyceridemia and hypercholesterolemia. The quality standard of Acipimox capsule in Part II of the Chinese Pharmacopoeia is the only official quality standard in China. Its content determination method is ultraviolet spectrophotometry. The determination method of the existing technology is as follows:
[0003] Determination method: UV-visible spectrophotometry;
[0004] Solvent: water;
[0005] Blank solution: solvent;
[0006] Reference solution: Take an appropriate amount of acipimox reference substance, weigh accurately, dissolve in water and quantitatively dilute to make a solution containing about 8 μg per 1 ml;
[0007] Test solution: Take the contents under the item of filling volume difference, grind, mix, accurately weigh an appropriate amount of fine powder (equivalent to 50 mg of acipimox), place in a 250 ml volumetric flask, add an appropriate amount of water, sonicate to dissolve the acipimox, dilute to the mark with water, shake well, filter, accurately measure 2 ml of the filtrate, place in a 50 ml volumetric flask, dilute to the mark with water, shake well;
[0008] Take the test solution and the reference solution and measure the absorbance at a wavelength of 264nm respectively.
[0009] The prior art requires two-step dilution in the preparation of the test solution, and has poor sensitivity, accuracy and specificity. Summary of the invention
[0010] In order to solve the technical problems mentioned in the above background technology, the present invention provides a high performance liquid chromatography method for determining the content of acipimox capsules, and the technical scheme adopted is as follows:
[0011] Prepare reference solution and test solution respectively, inject the reference solution and test solution into the chromatograph, record the chromatogram and calculate the content of acipimox capsules.
[0012] Preferably, the solution preparation steps are as follows:
[0013] Reference solution: Take an appropriate amount of acipimox reference substance, weigh accurately, dissolve in water and quantitatively dilute to make a solution containing about 0.2 mg per 1 ml;
[0014] Test solution: Take the contents under the item of filling volume difference, grind them finely, mix them evenly, take an appropriate amount of fine powder, accurately weigh it, dissolve it in water and quantitatively dilute it to make a solution containing about 0.2 mg per 1 ml.
[0015] Preferably, the chromatographic conditions of the chromatograph are as follows:
[0016] Chromatographic column: Octadecylsilane bonded silica gel is used as filler;
[0017] Mobile phase: methanol-0.01 mol / L tetrabutylammonium hydroxide solution;
[0018] Diluent: water;
[0019] Running time: 15min;
[0020] Column temperature: 30°C;
[0021] Flow rate: 1.0ml / min;
[0022] Detection wavelength: 264nm;
[0023] Injection volume: 10 μl.
[0024] Preferably, the calculation formula is as follows:
[0025]
[0026] in:
[0027] A pair, A supply: main peak area of reference solution and test solution;
[0028] V vs. V for: dilution volume of reference solution and test solution;
[0029] W for reference and W for test: sample weight of reference and test sample;
[0030] Specification: 250mg, refers to the amount of acipimox in each capsule;
[0031] Average filling volume: the average filling volume of 20 capsules, mg. The amount here refers to the total amount of acipimox and excipients contained in each capsule.
[0032] The present invention has the following advantages: the high performance liquid chromatography method has strong specificity, high sensitivity, good accuracy, and a simple test sample solvent preparation process without a secondary dilution step, which effectively reduces operating errors and improves detection efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 is the blank solvent chromatogram of the present invention;
[0034] Figure 2 It is the blank auxiliary material solution chromatogram of the present invention;
[0035] Figure 3 It is the chromatogram of the reference substance solution of the present invention;
[0036] Figure 4 The chromatogram of the test solution of the present invention is shown;
[0037] Figure 5 is a linear graph of acipimox content of the present invention;
[0038] Figure 6 This is a graph showing the recovery rate of 80% concentration of acipimox in the present invention;
[0039] Figure 7 This is a graph showing the recovery rate of 100% concentration of acipimox in the present invention;
[0040] Figure 8 This is the recovery rate spectrum of 120% concentration of acipimox in the present invention.
[0041] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0042] Example 1: Liquid phase method for determining the content of acipimox capsules.
[0043] (1) Chromatographic conditions:
[0044] Chromatographic column: Octadecylsilane bonded silica gel is used as filler;
[0045] Mobile phase: methanol-0.01 mol / L tetrabutylammonium hydroxide solution (pH adjusted to 6.0 with phosphoric acid); isocratic elution diluent: water;
[0046] Running time: 15min;
[0047] Column temperature: 30°C;
[0048] Flow rate: 1.0ml / min;
[0049] Detection wavelength: 264nm;
[0050] Injection volume: 10 μl;
[0051] (2) Sample preparation:
[0052] Solvent: water;
[0053] Reference solution: Take an appropriate amount of acipimox reference substance, weigh accurately, dissolve in water and quantitatively dilute to make a solution containing approximately 0.2 mg per 1 ml.
[0054] Test solution: Take the contents under the item of filling volume difference, grind them into fine powder and set aside. Take an appropriate amount of fine powder, weigh it accurately, dissolve it in water and quantitatively dilute it to make a solution containing about 0.2 mg per 1 ml.
[0055] like Figure 1 As shown, blank solvent was injected into the chromatograph and the chromatogram was recorded. No peak appeared at the acipimox peak (about 7.5 min), and there was no interference with the determination of this product.
[0056] like Figure 2 As shown, the blank excipient solution was injected into the chromatograph and the chromatogram was recorded. No peak appeared at the acipimox peak (about 7.5 min), and there was no interference with the determination of this product.
[0057] like Figure 3 As shown, the reference solution was injected into the chromatograph and the chromatogram was recorded. Acipimox peaked at a retention time of 7.515 min.
[0058] like Figure 4 As shown, the test solution was injected into the chromatograph and the chromatogram was recorded. Acipimox peaked at a retention time of 7.513 min.
[0059] The calculation formula is as follows:
[0060]
[0061] Example 2: Specificity and system suitability experiments.
[0062] The solvent (water) has no interference with the determination of the content of acipimox capsules, and the specificity of the present invention is good; the reference solution is continuously determined for 6 times, and the RSD of the main peak retention time and peak area are both less than 2.0%, and the applicability of the system of the present invention is good. Figure 3 .
[0063]
[0064] Example 3: Linearity and range.
[0065] like Figure 5 As shown, within the concentration range of 0.04 mg / ml to 0.24 mg / ml, the linear equation of acipimox is y=630.3056x+0.4602, r=1.0000, and the linearity is good (correlation coefficient r≥0.999).
[0066] Example 4: Recovery rate experiment.
[0067] like Figure 6-8As shown, the recovery of acipimox was 98% to 102%, the average recovery was 100%, and the RSD was 0.4%.
[0068] Example 5: Precision experiment.
[0069] The average repeatability of 6 samples was 100.5%, RSD was 0.5%; the average intermediate precision of 12 samples was 100.3%, RSD was 0.6%. Figure 4 .
[0070] Example 6: Durability test.
[0071] The chromatographic conditions were fine-tuned (see the table below), and the ratios of each durability content to the proposed condition content were between 99% and 101%:
[0072] Chromatographic conditions Range of change Flow rate ±0.1min Column temperature ±2℃ pH ±0.1 Organic phase ratio ±2% Chromatographic columns Batches of different brands (octadecylsilane bonded silica gel as filler)
[0073] Example 7: Comparison of the method of the present invention with other methods.
[0074] The method for detecting the content of Acipimox Capsules in the Chinese Pharmacopoeia is UV-Vis spectrophotometry, while the method for detecting the content of Acipimox Capsules in the present invention is high performance liquid chromatography. The specific results are shown in the following table:
[0075] method Chinese Pharmacopoeia Method Method of the present invention Test results 97.3% 97.5% Advantages of the method / Good specificity, high sensitivity and high accuracy Insufficient methods Requires two-step dilution and has poor sensitivity, accuracy, and specificity /
[0076] Therefore, the analytical method of the present invention has the advantages of good specificity, high sensitivity, high accuracy, etc. for determining the content of acipimox capsules.
[0077] The present invention is simple to operate, convenient to use, and suitable for comprehensive promotion and application. Although the embodiments of the present invention have been shown and described, it is understood by those skilled in the art that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and spirit of the present invention, and the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A high performance liquid chromatography method for determining the content of acipimox capsules, It is characterized in that Prepare reference solution and test solution separately, inject the reference solution and test solution into liquid chromatograph, and calculate the content of acipimox by peak area according to external standard method.
2. A high performance liquid chromatography method for determining the content of acipimox capsules according to claim 1, It is characterized in that The steps for preparing the solution are as follows: Reference solution: Take an appropriate amount of acipimox reference substance, weigh accurately, dissolve in water and quantitatively dilute to make a solution containing about 0.2 mg per 1 ml; Test solution: Take the contents under the item of filling volume difference, grind them finely, mix them evenly, take an appropriate amount of fine powder, accurately weigh it, dissolve it in water and quantitatively dilute it to make a solution containing about 0.2 mg per 1 ml.
3. A high performance liquid chromatography method for determining the content of acipimox capsules according to claim 1, It is characterized in that The chromatographic conditions of the chromatograph are as follows: Chromatographic column: Octadecylsilane bonded silica gel is used as filler; Mobile phase: methanol-0.01 mol / L tetrabutylammonium hydroxide solution; Diluent: water; Running time: 15min; Column temperature: 30°C; Flow rate: 1.0ml / min; Detection wavelength: 264nm; Injection volume: 10 μl.
4. A high performance liquid chromatography method for determining the content of acipimox capsules according to claim 1, It is characterized in that The calculation formula is as follows: in: A pair, A supply: main peak area of reference solution and test solution; V vs. V for: dilution volume of reference solution and test solution; W for reference and W for test: sample weight of reference and test sample; Specification: 250mg; Average filling quantity: average filling quantity of 20 capsules, mg.
Citation Information
Patent Citations
Acipimox film-controlled slow-release pellet capsule
CN103211785A
Acipimox sustained release tablet and preparation method thereof
CN115475148A
